High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer

Obstetrics and Gynecology

Volumn 123, Issue 1, 2014, Pages 57-64

  Thomsen, Louise T ^a,b,c   Frederiksen, Kirsten ^a,b,c   Munk, Christian ^a,b,c   Junge, Jette ^a,b,c   Castle, Philip E ^a,b,c   Iftner, Thomas ^a,b,c   Kjaer, Susanne K ^a,b,c,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Global Cancer Initiative   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; DENMARK; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERY ELDERLY; VIRUS DETECTION; WART VIRUS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DENMARK; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84893660645     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000056     Document Type: Article

References (38)

1. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000;86:429-35.
2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(suppl 5):F88-99.
3. Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012;30:3044-50.
4. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
5. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-96.
6. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
7. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102:1405-10.
8. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
9. Castle PE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012;30(suppl 5):F117-22.
10. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
11. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
12. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010;11:1048-56.
13. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjosé S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
14. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
15. Dahlström LA, Ylitalo N, Sundstrom K, Palmgren J, Ploner A, Eloranta S, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127:1923-30.
16. Sundström K, Eloranta S, Sparén P, Arnheim Dahlström L, Gunnell A, Lindgren A, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19:2469-78.
17. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
18. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
19. Wheeler CM, Hunt WC, Schiffman M, Castle PE; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291-9.
20. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-71.
21. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 2011;118:4-13.
22. Danish National Board of Health. Screening against cervical cancer-recommendations [in Danish]. Copenhagen (Denmark): Danish National Board of Health; 2007.
23. Danish National Board of Health. Screening against cervical cancer-recommendations [in Danish]. Copenhagen (Denmark): Danish National Board of Health; 2012.
24. Iftner T, Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003:80-8.
25. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39(suppl):22-5.
26. Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health 2011;39(suppl):72-4.
27. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976;38:290-5.
28. Aalen OO, Johansen S. Empirical transition matrix for nonhomogenous Markov-chains based on censored observations. Scand J Stat 1978;5:141-50.
29. Nielsen A, Iftner T, Nørgaard M, Munk C, Junge J, Kjaer SK. The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women. Sex Transm Infect 2012;88:627-32.
30. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
31. Castle PE. Abuses in human papillomavirus DNA testing. Obstet Gynecol 2011;118:1-3.
32. Silins I, Wang Z, Avall-Lundqvist E, Frankendal B, Vikmanis U, Sapp M, et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999;80: 2931-6.
33. Luostarinen T, af Geijersstam V, Bjørge T, Eklund C, Hakama M, et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999;80:818-22.
34. Anttila A, Ronco G; Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009;45:2685-708.
35. Barken SS, Rebolj M, Andersen ES, Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012;130:2438-44.
36. Naryshkin S, Austin RM. Limitations of widely used highrisk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug Healthc Patient Saf 2012;4: 167-72.
37. Zhao FH, Hu SY, Bian JJ, Liu B, Peck RB, Bao YP, et al. Comparison of Thin Prep and Sure Path liquid-based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathol 2011;119:387-94.
38. Carreon JD, Sherman ME, Guillén D, Solomon D, Herrero R, Jerónimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26:441-6.